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Blood coagulation research constitutes an important chapter of hematology
and strives to resolve problems of lively interest in medicine. Blood coagulation
physiology plays a predominating role in many medical fields. During the last
three decades blood coagulation physiology has been disclosed with significant
progress. So, it is not surprising to see that the practising physician, who is
not directly interested in blood coagulation, has difficulties in following all the
rich literature; and learning the terminology concerning this progressing field.
(Table 1). This article, which has been written with this goal in view, con-
tains our 01d1, ~l and many newl~O.1~4.1~5.1~9.-164works on this subject.
HISTORICAL SURVEY
From the time of Hippocrates, it was known that blood flowing out of an
injured vessel coagulates in a short time. The mechanism of this event remained
unkown for a very long time. By means of the literature which is at our dis-
posal. we know that MALPIGHI1 was the first to study the problem of blood
coagulation. He was the investigator who succeeded to show in 1683 that
when coagulated blood is washed, one can obtain a fibrous whitish mass
(the fibrin). However, the name "fibrin" was not created by Malpighi but by
CHAPTAL2 a century later. This French investigator reported that the part that
coagulates is not the formed elements of the blood, but the fluid part, - that
p~rt called "fluid lymph" by HEWSON1 in 1770. The mechanism of fibrin forma-
tion was described first in 1844 by an English investigator BucHANAN2• This
author thought that coagulation occurred not spontaneously with fibrin, but
through the interaction of some other factors (1845) or ferments which became
active outside the body. MORAWITZ considers3 BUCHANAN2 as the founder of
modern coagulation research. The so-called Buchanan theory can be summa-
rized by the following formula:
Permanent address: 11 Adolf-Kronerstr., Stuttgart-a, F. R. of Germany.
* To my previous teacher and Nobel Prize winner Prof. A. SZENt-GYORGYI
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Table 1
The Clotting Factors (Names According to International Blood Clotting Nomenclature
Committee) and the Hemorrhagic Disorders in Relation with the Factors.
Defect
.1
of:
Clot promoting
factors
II
Hemorrhagic
syndrome ICongenital HIAcquired
Coagulopathy :
I
Liver disease,
Fibrinogen
Afibrinogenaemia, Medullary tumors,Fact. I Hypofibrinogenaemia, + Fibrinolysin defibri-Fibrinogenopenia
nation
Fact. II Prothrombin Hypothrombinaemia + Liver disease aftercumarine
Fact. III. Thrombokinase- see Fact. V-XIIThromboplastin
Fact. IV Calcium
Proacelelerin Parahaemophilia Liver parenchymalFact. V (Ac-Globulin, SPCA) (Owren) + damages; Fibrino-lysis: Liver disease
Fact. VI Accelerin
Liver parenchymal
Fact. VII Proconvertin Prooenvertinaemia + damages (diseases)after cumarine
treatment
Fact. VIII Antihaemophilic Haemophilia A + several liver diseasesGlobulin A Fibrinolysis
(Antihaemophilic
Fact. IX Globulin B) Plasma- Haemophilia B + Live::r parenchymalthromboplastin Christmas disease + damages (diseases)Component-PTC
Fact. X Stuart-Prower-Factor Stuart-Prower·Fact. + after anticoagulantsDefect cumarine
Fact. XI Plasmathromboplastin- PTA-defect + several liverantecedent-PTA cirrhosis
Fact. XII Hageman.Factor Hafeman.Factor- + ?De ect
Fact. XIII Fibrin establishing(Laki- Factor (Fibrinase) + ?LOrfmd)
Coagulation Inhibitors
Inhibitor of the first phase
..(Antithrombin? Antithrombokinase?)
Inhibitor of the 2nd phase (Antithrombin)
..
and others (see the schema of fibrinolysis)
So-called antibody hemophilia
Liver disease, allergic states
purpura fulminans, purpura
abdominalis, heparin action.
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Buchanan's Ferment (Thrombin, according to
Schmidt, later on)
Blood 1 Fibrin
In 1832, Johannes MULLER2 described one of the important coagulation factors,
namely, the fibrinogen. The name" fibrinogen" was created by VIRCHOW2 who
postulated the existence of a relation between blood coagulation and oxygen.
The successful isolation of fibrinogen from sulfate-plasma through precipitation
by sodium chloride led the French investigator DENIs2 to use the name "plasmin"
in 1856. One year later, in 1857, the physiologist Ernst BRucKE2 (1819--1892)
pointed out the important role of the vascular wall in blood coagulation.
De BLAINVILLE2 showed in 1834 that the intravenous injection of cytoplastic
substances such as brain extracts produced massive intravascular coagulation in
experimental animals. However, a long period of time passed before we were
able to understand that the cytoplastic substances of Blainville, and the ferment
of Buchanan, were not similar. The great physiologist Alexander SCHMIDT4
(1841--1914), the pupil of Felix Hoppe-Seilers, discovered (1892--1895) that
these two substances were different from each other. According to SCHMID-r64,
during the blood clutting proccss, the ferment of Buchanan was formed out of
a supposed precursor, under the influence of "Protozym" (SCHMIDT and RAu-
SCHENBACH) or "cytoplastic substance" (SCHMIDT) or "thrombokinase "+ (MoRA-
WITZ). The ferment of Buchanan was called "thrombin" by SCHMIDT and its
precursor "prothrombin ". Accordingly, the blood coagulation theory of Alex-
ander SCHMITD was as follows:
Cytoplastic substances
Prothrombin -----------------1 Thrombin
Thrombin
Fibrinogen ~ Fibrin
It is interesting to note that Schmidt did not take into consideration the role of
the last factor, namely, calcium in coagulation; although ARTHUS and PAGES had
shown, as early as 1891, that coagulation is impossible without calcium. Two
Swedish chemists from the University of Uppsala, PECKELHARJNd (1891) and
HAMMERSTEN2 (1941--1932) demonstrated that calcium is necessary for the
actio nof Protozym. HAMMERsTEN2 had also demonstrated that, although cal-
cium was necessary for the first phase of blood coagulation, it was not needed
in the second phase.
MORAWITZ who also insisted on the importance of calcium in coagulation,
proposed in 1905 the following scheme which became classical:
+ Thrombokinase (Europ. literature)=Thromboplastin (America literature).
3
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1st phase: Prothfombinl
Thrombokinase (Thromboplastin)
Ca i 1
2nd phase: Fibrinogen +Thrombin~Fibrin
The works of Morawitz have cleared up many contradictions which existed
on this subject in the earlier publications. The activation of prothrombin, dis-
covered by SCHMIDT\ which occurs through alkali-reactivation of blood serum
and was shown not to be the normal pathway. MORAWITZ and WOHLlSCH~
discovered that the alkali-reactivation of blood serum proposed by SCHMIDT was
not the real activation of prothrombin, but it was rather a reaction which
reversed the inactivation of thrombin that occurs in the serum shortly after
coagulation. This substance in the serum which can be activated in this manner
and which is, according to our knowledge today an association of thrombin
with antithrombin, was called Metathrombin hy MORAWITZ3 (WOHLISCH5). The
theory of Morawitz given above may be called the "theory of 4 factors".
Accordiug to MORAWITZ, four factors were necessary for blood coagulation.
namely: prothrombin, thrombokinase, ionized calcium and fibrinogen. Some
other theories appeared soon after that of MORAWITZ. For example, NOLF3
proposed in 1908 his theory on blood coagulation with five factors and three
phases. The five factors are: calcium and four other factors of proteinic nature
in plasma, namely, thrombokinase, thrombozyme, thrombogen and fihrinogen.
According to NOLF6, plasmakinase is a tissue-kinase of lipoproteinic nature,
which accelerates the reaction of thrombozyme and thrombogen in the presence
of calcium. He thinks that thrombin results from the association of these two
factors. In 1912 DELANGE2 and the great Belgian serologist and Nobel prize-
winner BORDET2 presented a similar theory with five factors. BORDET2 and the
American physiologist HowELL4 worked independently and reported that the
theory of SCHMIDT was acceptable. Both authors came to the conclusion that
the active component of Morawitz's thrombokinase was a lipoidic substance,
considered by HOWELL to be a cephalin. McLEAN9, a student working in Howell's
laboratory7 in 1916 discovered heparin. It is an inhibitor occurring in the body
and active in vivo and in vitro. According to the research of McLEAN, heparin
works as an antithrombin which inhibits the formation of thrombin from pro-
thrombin. The modern era in blood coagulation research began in 1934. This
era is characterized by the fact that, theoretical knowledge was put gradually
and progressiyely into practical therapeutic use. To begin this new era of blood
coagulation research, we have to mention first of all, the distinguished discovery,
honored with the Nobel prize, of SZETGYROGY (Vit. C +P) (Vasal Wall)* and
* Under Prof. Szent-Gyorgyi's influence developed particulary the author(SZIRMAI)several years
ago the instruments besides registering the muscle and nerve functions, also for the mesurement
of capillary-fragility
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Eig. 1 Angio-Myograph by SZIRMAI for the determination of capillary resistance
and fragility also by haemorrhagic diatheses etc. but also for the determination for vasal,
muscular and other conditions in pathologic and physiological cases. (New prototype fact.
Mr. Franz PRINZ (MSG) Dagersheim Production: Dr. E. HENSCHEN, Fabrik Technische
Messinstrumente, Sindel£ingen, F. R. of Germany)
First instrument in this direction was developed by Dr. SZlRMAI 18 years ago parti-
cularly under the influence of his previous Professor, Nobel prizewinner A. SZENT-
GyORGYI.
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Henrik DAM29 who showed the absolute necessity of vitamin K for the synthesis
of prothrombin. The description in 1935 of prothrombin determination by
QUICK10 constituted a definite advance and provided, in a decisive manner, the
progress of the works on Dicumarol and vitamin K. From this time, many
authors made contributions to the classical coagulation scheme and enlarged upon
it. OWRENll showed that besides the four known factors, that is Fibrinogen (I),
Prothrombin (II), Thromboplastin (III) and Calcium (IV), another factor existed
in coagulation. The active form of this factor, shown as VI was necessary for
the conversion of prothrombin into thrombin. KOLLER12 recommended the use
of numbers to replace the names of clotting factors and soon factor VII was
described as an accelerator of the prothrombin conversion. The investigations
on hemorrhagic syndromes constituted an important section of blood coagulation
research. It was shown that platelets were necessary for the formation of blood
thromboplastin and to achieve this, they had to react with some plasmatic
factors: the antihemophilic globulin A (AHG: factor VIII), the antihemophilic
globulin B (factor IX), and factors X, XI, XII and XIII. The classic view
accepted that the action of prothrombin depended on three factors and that many
factors (namely, the platelet factors 1, 2, 3 and plasmatic factors 8, 9, 10) were
necessary for the formation of blood thromboplastin. The deficiencies of these
factors determine definite diseases. The deficiency of factor VIII is called
Hemophilia A, that of factor IX, Hemophilia B and that of factor X Hemophilia
Co. Blood coagulation is completed in three phases according to the classical
5
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theory. Later on, this theory or scheme was enlarged upon. So, MARBET and
WINTERSTEINt7 and also SZIRMAI159 have added to the classical scheme a prephase
dealing with platelet functions and a terminal phase describing the disintegration
of fibrin (Table 2).
Table 2
This Scheme is for the Blood-clotting so Important, as Mendeleeff's
Periodical System for the Chemistry
B/ood.C/otting.Scheme
According to Szirmai (1954-/965)
I. Phase .h~ Phase .Dl. Phase]l'omation of
throaboplaetill ]l'o:.oation of tbroIlbin ]l'oJ'lllation of fibrin
PROPHASE
1st Phase: The Ponnation of Thromboplastin: In order for clotting
to occur, active thromboplastin must circulate in the blood. This may happen
in two ways:
1. Blood may extravasate and mix with thrombokinase..
2. Thromboplastin may be activated auto-catalytically in blood. This
process is not completely understood. Most of the authors (FONI018,
FEISSLy19, OWRENw, HORANYI%\ etc.) share the view of MORAwITz, which
states that the foreign surface activation of platelets results in the
formation of active thromboplastin. BIZZOZER022, the discoverer of
platelets, was also the first to recognize the unique role of platelets in
physiological hemostasis and their importance in the pathogenesis of
thrombosis.
According to MILSTON23, precursor of thromboplastin activates itself under
6
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the influence of ionized calcium in plasma. LENGGENHAGER24 thinks that an
enzyme named Thrombokatalysine is necessary for this activation. KUDRJASCHEW
and UTILINA25 share the same view, but they call thrombotropin the activating
enzyme. Others, among whom one may mention VIRCHOW,WIDENBAUER and
REICHEL16 and some authors28 think that blood coagulation is in relation with
respiration. WIDENBAUER and REICHEL26 believe that the thrombokinase is acti-
vated bceause of the decrease in carbon-dioxide levels of extravasated blood.
The investigation of LAKI 30 seemed to confirm the existence of a precursor of
thrombokinase. According to QUICK, the inactive precursor of the thrombo-
kinase is activated by means of an enzymatic substance which may originate
from decayed platelets.
For a long time, it was assumed that active thrombokinase resulted from
the interaction of plasmatic and platelet factors. We also know that thrombo-
kinase is present in great quantities in tissues, such as lungs, brain, placenta,
etc. We have also used the amniotic fluid of SZIRMAIs2 as thrombokinase (BARON
C. et at., Nucl. Hemat., March·May, Vol. III, Nr. 2, 167, 1964). The latter
plays important roles in all phases of coagulation, but is primarily active on
platelets. The authors believe that all the above-mentioned reactions begin with
the alterations taking place in platelets, after agglutination or after contact acti-
vation. BRINKHOUSsO has found that the foreign contact causes an activation of
thrombocytolysin which in turn destroys the platelet membrane. According to
. MAEBET and WINTERSTEIN, the contact with histamine or histamine-like substance
causes the disintegration of the platelets. Electron microscope studies reveal that
histamine prevents or loosens platelet agglutination. A strong vasoconstrictor,
Serotonin (5-oxytryptamin) is liberated from disintegrated platelets. Then the
injured vessel is constricted. The quantity of extravasated blood remains mini-
mal and this serves a hemostatic purpose. MARBET and "WINTERSTEIN33 and M.
B. ZUCKER36,37 reported that the vascular contraction begins 15 seconds after the
injury to the vessel, and at the end of one minute the lumen may be narrowed
up to 80 percent of its initial. STEFANINl38 suggested that Retraktozym (FONld9)
is a definite platelet factor which accomplishes the retraction of the clot. The
platelets also contain the antifibrinolysin. According to the works of STEFANINI38,
CREVELD40, ]URGENS41 and SEEGERS42, the platelets possess three factors that are
active in blood coagulation:
1. Platelet factor 1 accelerates the conversion of prothrombin into throm-
bin and is probably identical with factor V ;
2. Platelet factor 2 supports the influence of thrombin; and
3. Platelet factor 3 is a factor takIng part in the formation of thrombo-
plastin, reacting together with factors VIII, IX and X.
Platelet factor 3 also possesses anti-heparin activity. In cases of total or partial
7
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deficit of this factor, as in thrombopathy, antithrombin of the heparin-type
will be generally increased because of lack of platelet factor 3 neutralization
(SZIRMAI, JURGENS and others43). Deficit of platelet factors causes various hae-
morrhagic diatheses. In the table below, we perceive the platelet functions
known up to 1955 :
Platelet factor 1
-+accelerates the reaction
Prothrombin~ ThrombinPlatelet factor 3
Thromboplatin forming
and anti-heparin factor Platelet factor 2
-+accelerates thc reaction
Fibrinogen ----+ Fibrin
Table 3 also shows platelet factors active in blood coagulation (1961).
Table 3
Platelet Factors Active in Coagulation
Names Function and Properties
1. Platelet factor 1
2. Thrombin-accelerator
3. Platelet factor 3
4. Antiheparin factor
5. Clottable factor
6. Platelet's co.thrombopla!:>tin factor
(viper-venom factor)
7. Thrombosthenin (Retractozyme)
8. Antifibbinolysin
9. Fibrin stabilizing factor (Fibrinase)
10. 5·Hydroxytryptamin (Serotonin)
Factor V-like activity. Probably identical
Accelerates thrombin's action and the con-
version of fibrinogen into fibrin
Takes active part in the formation of
thromboplastin
Nentralizes the inhibitory action of heparin
Identical with fibrinogen
Action sinilar to that of factor VII.
Accelerates the conversion of prothrombin
into thrombin through the action of viper
venom
Actomyocin-like factor. Takes part in clot
retraction
Inactivates the fibrinolysin
Inhibits the lysis of fibrin clot in urea
Vasoactive (constrictor) factor
The investigators believed in the beginning (MORAWITZ, NOLFs.6) that
thrombokinase was a compound which could be defined chemically, containing
one part of phosphatide and another of protein nature. Today this concept
is accepted only for tissue thrombokinase (extracts of brain, lung, placenta,
8
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amniotic fluid and others) but not for blood thrombokinase. BIGGS47 advanced
that the product of the reaction of platelet factors with plasmatic factors (VIII,
XIV and X) is the equivalent of tissue thrombokinase. Tissue thrombokinase
is a lipoprotein (FEISSLY, CHARGAFFgl.4~) relatively stable. STUDER46 divided this
lipoprotein by means of ether into two parts: 1. a factor of lipidic nature,
which is thermostable and of cephalin type; and 2. the proteinic part which is
thermolabile. When they are combined, these two parts assume their full acti-vity.
Blood thromboplastin is the end-product of the reaction between pletelet
factor 3, antihemophilic globulin, factor IX and factor X.
Factor VIII or antihemophilic globulin is a very labile plasmatic factor of
proteinic nature. It is found with fibrinogen and in Cohn's fraction number
one. Antihemophilic globulin activity disappears rapidly in stored blood. Coa-
gulation of blood also consumes it.
Factor IX or Christmas factor of Biggs and MACFARLANE44 is probably the
same factor called plasma thromboplastin component (PTC). It is stable in
stored blood and can be shown in serum after blood clotting. Therefore the
treatment of hemophilia B, the disease due to the deficiency of factor IX, is
possible with stored blood.
Factor X (Stuart·Prower factor) is decreased during cumarin treatment and
its normalization after the withdral of the medicament is slower than that of
stable factor (factor VII).
The thromboplastin generation test (BIGGS47), DUCKERT48) gives us valuable
information about the mechanism of blood thromboplastin formation. Other
interested factors are factors XI, XII and XIII (see Tables 1 and 6).
2nd phase: The Conversion of Prothrombin into Thrombin: The
study of the literature which we summarized above shows clearly that authors
agree with the existence of two separate thrombokinase systems leading to blood
coagulation (SCHWICKuo, SZIRMAI1~1). According to this agreement, DEUTSCH162
proposed to differentiate two types of mechanisms in blood coagulation, namely,
the exogenous (extrinsic) and the endogenous (intrinsic) systems.
As we have mentioned above, during intrinsic blood coagulation, the pro-
thrombin is converted into thrombin through the action of blood thromboplastin.
As it can be seen from our coagulation schemes in 1955 and in 19601~6, blood
thromboplastin formation starts with contact activation, and progresses through
the intermediary of various active products. Factor XII (Hageman factor),
activated by foreign surface contact activation reacts with factor XI (PTA) to
form a labile product, which enters into reaction with factors VIII, IX, X,
XIII and calcium. Thus intermediary propuct I is formed. The intermediary
product I and platelet factor 3 act together to prepare the intermediary product
9
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2 which, under the influence of active factor V, forms blood thromboplastin.
The most severe coagulation disorders in hemorrhagic diatheses are encountered
in the formation of blood thromboplastin. Besides cases with one factor-defect,
there are cases with multiple defects of thro~lboplastinic factors. For example,
KOLLERlaS reported hemophilia A case deficient also in factor VII. In Owren's
parahemophilial~)and in carcinoid syndrome (SZIRMAI101) deficiencies of factors V
and VIII are associated. In thrombopathy of Willebrand-Jiirgens type, platelet
defect is associated with deficiency of factor VIII (Table 1).
SCHWICK100 thinks, together with other authors, that a continuous latent
coagulation takes place in the vessels which probably causes minimal deposits of
fibrin on the endothelial surface. Some authors suppose lOJ that factor VII arises
from prothrombin in peripheral blood and probably on its return to the liver is
again transformed to prothrombin. This concept is in concord with the
works of SEEGERS and collaborators1oo who have shown, by chemical methods
that factor VII (Autoprothrombin I) and factor IX (autoprothrombin II) derive
from prothrombin.
The works on latent intravascular blood clotting are especially important in
learning the relative changes in coagulation dynamics during extra-corporal
circulation.
Recently, many new factors have been added to the above-mentioned three
platelet factors active in coagulationloo.loo (Table 3). GROSS and collaborators106
have shown a deficiency of "glyceraldehyde phosphatedehydrogenase" and of
"pyruvate kinase" activities in thrombasthenia of Glanzmann. Upon adding
these enzymes to platelets, the defective coagulation activity is corrected.
We investigated107 the activity of "succinildehydrase" activity of the plate-
lets. LUSCHER and collaborators have shown the presence, in the platelets of a
contractile protein, the" retractozyme ", of a structure similar to that of acto-
myosin, probably interested in the retraction of the clot.
Now we shall take a look on the process of the conversion of prothrombin
into thrombin.
In the classical theory of MORAVITZ3, we find the conversion of prothrombin
into thrombin. For this conversion, it has been shown that calcium and throm-
boplastin are necessary, and recently factors V and VII. According to chemical
investigations, especially by SEEGERS, LOOMIS and VANDERBELT49, pure prothrom-
bin is a glucoproteide, soluble in water and containing sulphur. The isoelectric
point is about pH 4.8. It is found in Cohn's fraction III/2. In comparison with
other factors, prothrombin is relatively stable. Storing of the blood diminishes
its activity only slightly. It can be stored in frozen plasma for very long time.
Methods of adsorption, such as barium sulfate or calcium phosphate adsorption
and Seitz filtration are able to take it off the plasma. According to HOWELL and
10
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HOLT" prothrombin circulates in blood, in a bound form with heparin; and
thromboplastin neutbalizes heparin, thus liberating prothrombin. According to
DUCKERHOF and MARylw, prothrombin does not exist as such in the blood, but
circulates in the form of thrombin bound to natural anticoagulants. Thrombo-
plastin is supposed to neutralize the anticoagulants and set free the thrombin.
COPLEY also is accepting this view5\ OWRE~8 showed that storage of plasma
shortens the prothrombin time. The investigations of QUICK and HussEy5Us
suggest that prothrombin is partly bound with heparin. Only that part which
is free can take part in thrombin formation. The decrease in the amount of
bound prothrombin or the increase in free prothrombin increases also antithrom-
bin activity. One-step prothrombin time test measures only free prothrombin.
Besides the above-mentioned authors, many others have studied the problem of
free and bound prothrombin (V£SZI, KOVACS and GESZTIM ). The existence of
factor V was first forwarded by NOLF6 under the name of Thrombogen. Factor
V is called frequently Proaccelerin and it has many other names as will be seen
in Table II at the end of this article. Factor V is a hydrosoluble globulin; its
activity decreases on storage in room temperature and when heated to 56°C, it
is inactivated spontaneously. MARJiET and WINTERSTEIN55 have seen that the
activity of factor V decreases in oxalated blood, after storage of some hours.
This fact leads to prolongation of prothrombin time and the control of dicumarol
therapy becomes falsified. Deficiency of factor V is called parahemophilic or
Owren's disease. SZIRMAI81 reported factor V deficiency in cases of genital
carcinoma in women. Factor V is not adsorbed by barium sulfate. Thrombin
activates factor V and accelerin (factor VI) is formed.
Factor VII has many synonyms (see end of the article). Its existence was
supposed by BORDET and DELANGE in 191256• However, these authQrs had
mistaken it for prothrombin. QUICK57 thinks even now that factor VII is an
inactive precursor of prothrombin (prothrombinogen). He thinks that factor VII
is present in plasma, although its activity is higher in serum61• Therefore, some
authors58 think that factor VII is found in plasma in the form of an inactive
precursor.
Prothrombin, factors V and VII constitute together the so-called prothrom-
bin-complex. Thromboplastin and the accelerator factors catalyze coagulation,
but do not take part in it. Therefore, thromboplastin will not be consumed but
will be found in serum as residual thromboplastin. The residual prothrombin
of the serum is under the influence of serum thromboplastin. Serum prothrom-
bin is consumed in approximately 24.-36 hours (KOVACS60). QUICK and FAVRE-
GILLy61 also have studied this problem.
Thrombin has an autocatalytic action, that means it accelerates and increases
its own quantitative formation. FISCHER62 was the first author to describe this
11
Szirmai: Blood coagulation from the beginning until to-day
Produced by The Berkeley Electronic Press, 1967
34 E. SZIRMAI
property. According to LAKI30, ASTRup63 and recently QUICK65, thrombin acce-
lerates the activation of Prothrombokinase. But OWREN58 thinks that thrombin
accelerates the conversion of factor V in factor VI and not the formation of
thromboplastin. QUICK57 believes that at the beginning of blood coagulation a
small quantity of thromboplastin is formed and it converts a small amount (0.1
percent) of prothrombin into thrombin. This thrombin acts upon the platelets
which yield 8--10 times more platelet factor 3 than the first time. This causes
a greater activation of thromboplastin which in turn transforms more prothrom-
bin into thrombin; This process goes so far that no thrombin or very little can
be found after it. Even this minimal thrombin, however, results in the secre-
tion of fibrinogen.
Thrombin is found in the albumin fraction of the plasma (AsTRuP and
DARLING96). Heating above 40°C inactivates it rapidly. The activity of throm-
bin is nowadays mostly measured in NIH units. One NIH-unit corresponds to
the amount of thrombin that clots 1 ml of a standard fibrinogen solution in 15
seconds at the temperature of 28°C.
3rd phase: Formation of Fibrin: Thrombin exerisces an enzymatic
influence on fibrinogen (EAGLE78, FERGUSON83, FREDERICQ89, WOHISCH70). It can
cause clotting of fibrinogen even in the proportion of 1/100,000. Fibrinogen is
a globulin of a molecular weight of 400,000, and it is found in Cohn's fractions
I and II. Fibrinogen solutions are not stable in room temperature and coagulate
when heated above 50°C.
The authors differ on the mechanism of fibrin formation out of fibrinogen.
FERRY and MORRISON71 think that thrombin causes the polymerization of fibrino-
gen in a three-dimensional manner and thus fibrin is formed. CHARGAFF72 be-
lieves that thrombin produces fibrin through oxidation of the amino-acid groups
of fibrinogen. According to LORANdS, thrombin separates a peptide molecule
of low molecular weight (fibrinopeptide) out of fibrinogen and then thrombin is
formed. ]ENEY, VALYI·NAGEY and VACZy74 and LYONSL5 share the view of
CHARGAFF. LAKI76 thinks that amino-acid groups play an important role in fibrin
formation and that thrombin acts on fibrinogen with the result of setting free
the amino-acid groups of the latter. Some authors (ApITz77) reported that there
is an intermediary substance, the profibrin, which is formed between fibrinogen
and fibrin.
THE LAST PHASE
Retraction and Fibrinolysis: The formed clot contracts on standing and
serum is squeezed out of its own and slowly. This event is called "retraction of
the clot". The optimal temperature of retraction is about 40°C. Platelets en-
hance clot retraction through their enzyme called "retractozyme". In cases of
12
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thrombocytopathy and thrombocytopeny the retraction occurs late or not at
all. This abnormality can be measured quantitatively by means of thrombelas-
togram (HARTERT78, MARBET and WINTERSTEIN17, SZIRMAI and JURGENS43).
As is known, during blood coagulation much thrombin is formed. The
organism has to neutralize it and there are two possibilities for this: 1. Throm-
bin is adsorbed on fibrin and thus it is bound; 2. Antithrombin inactivates
thrombin. Antithrombin is a natural anticogulant in the albumine fraction,
relatively thermostable and of lipoieic nature. Antithrombin binds thrombin and
forms an inactive complex, called "metathrombin ". According to the investi-
gations of GERENDAS, CSEFKO and UDVARDy79, the reaction between thrombin and
antithrombin is of a monomolecular type. Heparin accelerates the inactivation
of thrombin (HoRN, GERENDAS and BORsom80, SZIRMAI81).
Table 4
Synonyms of Coagulation Factors
Names Xr. Synonyms
Factor I Fibrinogen (DENIS)
Plasmin (DENIS)
Factor II Prothrombin (SCHMIDT)
Thrombogen (MORAWITZ)
Thrombozyme (NOLF)
Proserocyme (BORDET)
Prothrombin B (QUICK)
Plasmozyme (FuLD)
Factor III Thromboplastin (NoLF)
Thrombokinase (MoRAWITZ)
Zymoplastin (SCHMIDT)
Cytocym (BORDET)
Thrombokinin (LENGCENHAGER 121)
Factor IV Calcium (coagulation function:
ARTHUS and PAGES 1890)
Factor V Factor V (OWREN). Ac. globulin
Proaccelerin (OWRENI29)
Labile factor (QUICKI22)
Plasma Ac-globulin (WARE and SEEGERS428)
ThrombogElDe (NOLF)
Prothrombinase (OWREN)
Prothrombinogenase (OWREN)
Prothrombinokinase (MILSTON)
Plasma-prothrombin-conversion factor (PPCF) (STEFANINI)
Component A of prothrombin (QUICKI24)
Prothrombin accelerator (FANTL and NANCEI25)
Co·factor of thromboplastin (HONORATOI26)
Carcinophil-Factor (SZIRMAI)
Factor VI Factor VI (OWRENI27)
Found
in plasma
in serum
+-
+-
in tis.<;ue
+-
-+
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Accelerin (OWREN127)
Serum-Ac-globulin (WARE and SEEGERS)
Prothrombinase (OWREN)
ThrOmbinogenase (OWREN)
Serum accelerator (STEFANINI) (see factor VII!)
Factor VII Factor VII (KOLLER131) +-1-
Proconvertin (OWRENl29)
Serum prothrombin conversion accelerator
(SPCA) (De VRIES, ALEXANDERl32)
Convertin (133) activated form)
Stable factor (STEFANINIl30)
Serozyme (BORDET)
Kappa factor (SRBYE and DAM)
Prothrombinogen? (QUICK)
Co-Thromboplastin (MANN and HURNl35)
Serum accelerator (JACOX)
Prothombin accelelator (MAC MILLAN134)
Prothrombin conversion factor (OWREN)
Prothrombin convertin factor (JACOX)
Complements B Prothrombin (QUICK124)
Factor VIII Factor VIII (KOLLER) .j -
Antibemophilie Globulin (HG) PATEK and TAYLOR)
Antihemophilic Globulin A (CRAMER137)
Antihemophilic factor (AHF) (BRINKHOUS and other144)
Plasma thromboplastic factor (PTF) (RATNOFF138)
Plasma thromboplastic factor A (AGGELER)
Thromboplastic plasma component (TPC)(SHINOWARAI42)
Factor Antih~mophiliqueA (SoULIER)
Thromboplastinogen (QUICK)
Prothrombokinase (FEISSLy140)
Platelet co-factor (JOHNSON141)
Plasmakinin (LAKII43)
Thrombokatalysin (LENGGENHAGBR121)
Factor IX Plasma thromboplastin component (PTC) (AGGELER) + +
Christmas-factor (BIGGS and MAC FARLANEI45)
Antihamophiles Globulin B (CRAMERl37)
Plasma thromboplastic factor B (AGGELER146)
Plasma factor X (SCHULMAN)
Factor antih~mophiliqueB (SOULIER)
Maena-Factor? (147)
Factor X Stuart-Prower-Factor + +
Plasma thromboplastin factor (AGGELER12.13.15)
Factor XI Plasma thromboplastin antecedent (PTA) + +
(ROSENTHAL)
Factor XII Hagemann Factor + +
Factor XIII Fibrin stabilizing factor (FSF) + +
Fibrinase-Factor (FSF)
Laki-L6raand·Factor
Hungarian Factor (name after SZIRMAI for Laki-L6raad-factor)
14
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The last phase has a third step, namely "fibrinolysis" (Table 4). That
means the lysis or dissolution of retracted fibrin clot. Many inhibitors take part
in this process. For this reason, we shall study it together with inhibitors.
Inhibitors of Blood Coagulation: The inhibitors of blood coagulation
may be divided in two groupsl50; the physiologic ones and others. In the latter
group, cumarin derivatives and heparin, which are useful therapeutic tools in
thrombo-embolic conditions may be mentioned. Plasma antithrombin, anti-
thromboplastin and fibrinolysin play an important role, that of maintaining the
balance between the forces activating blood coagulation and those inhibiting it.
The physiologic inhibitors show their action in three manners:
1. Inhibition of prothrombin activity
2. Inhibition of thrombin
3. Complex inhibition.
Examples to the first group of anticoagulants are heparin and antithrombo-
plastin. Heparin also has other complex actions. The investigations of LAN-
CHANTIN and WARE82 show that plasma and serum possess a thromboplastin in-
hibitor. It can neutralize tissue thromboplastin in the presence of calcium.
There is another known factor, antiprothromboplastin, that is increased in some
pathologic states (hemophilia due to inhibitors). It inhibits the conversion of
Prothromboplastin into thromboplastin.
To the second group, heparin and antithrombin constitute two examples.
For the third group, heparin is the unique example. McLEAN83 discovered
heparin in the liver. It is an ester of mucotinpolysulphuric acid, containing
glucosamine, glucuronic acid and sulphuric acid (JORPES8" WOLFRAM85,RATHGEB86).
Contrary to that of the related chondroitin-sulfuric acid, its amino-group is not
acetylated, but sulfated. Heparin can be isolated from the liver as well as from
the lung, which possesses an activity of 16--2801.0. per mg of tissue. The
international standard preparation of heparin shows 1301.0. per mg. It is made
in Ehrlich's histiocytes. It is a strong acid, binding organic bases and thus
forming dissociable complexes. Heparin binds preferably protaminis (clupein
and salmin) and teluidine blue. HOLGREEN and WILANDER88 showed inhibition of
heparin with toluidine blue. Heparin does not act as anticoagulant when alone,
but only when it is in bound form (MELANDy89, QUICK90). FEISSLY and ENOWICZ91
reported that, when joined to the so-called cofactor of the plasma (albumin X),
heparin exhibits the properties of the polyvalent anticoagulant. HORN and
BORSODI92 think that heparin circulates partly in free form. When the blood
stands in a tube, the bound heparin passes progressively into the free form.
Protamin and toluidine-blue only bind free or disposable heparin. Heparin is a
physiologic shelter against hypercoagulability and compensates the activity of
procoagulant substances. The bound heparin holds probably prothrombin in an
15
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inactive complex. Heparin inhibits conversion of prothrombin into thrombin,
as well that of fibrinogen into fibrin. On the other hand, it inhibits the activity
of platelet factor 3 and consequently delays the formation of thromboplastin out
of plasmatic factors. Besides alpha-heparin, McLEAN and beta-heparin (MARBET
and WINTERSTEIN), the names gamma-3 and gamma-4 heparin have been given
to the inhibitors of inflammation and to menstruation inhibitors (SZIRMAI93)
(Table 5).
All factors and phases of fibrinolysis are shown in Table IV prepared by
SZIRMAI. From the study of this table, it emerges that fibrinolysis may be
divided in the following steps:
a) Prephase: Formation or activation of the activators
b) First phase: Activation of profibrinolysin
c) Second phase: Fibrinolysin formation or transformation of profibrino-
lysin into fibrinolysin
d) Third phase: Thrombolysis.
In the prephase two activators are demonstrable: the tissue activator or
tissue fibrinokinase and the blood activator (SZIRMAI169).
Dicumarol, synthetised by ANSCHUTZf4 in 1913 has been shown to cause
"sweet clover disease ", a hemorrhagic disorder in cattle. The inhibitor action
of cumarin on blood coagulation was shown in 1941 by LINK and COLL9\ and
attention was drawn to its resemblance with the disease in cattle. Contrarily to
heparin, cumarin does not reduce the reaction capacity of clotting factors, but
reduces the levels of those factors formed in the liver in presence of vitamin K,
namely the prothrombin and factors VII and X together with factor IX. Dicu-
marin which displays a chemical structure similar to that of vitamin K acts
probably by taking its place in coagulation events (competitive inhibition).
On the other hand, we have two antithrombotic substances working against
thrombin in different manner. The heparin-type antithrombin (ASTRUP and
DARLING96,ll9) also called thrombin inhibitor, behaves like a genuine enzyme;
that is, it is composed of a prosthetic group (heparin) and a corresponding co-
ferment, called cofactor (HOWELL and HOLT7), heparin complement (CHARGAFF,
ZJFF and MOORE98) and thrombin co-inhibitor (ASTRUP and DARLINd 6).
A completely different substance is shown by the so-called "serum anti-
thrombin ", which was known or assumed as present since the days of classical
blood coagulation theory (WOHLISH99, GRUNING100, SCHMIDT\ MORAwITz3). Many
authors60,96,lOl-107 have investigated the properties of serum antithrombin, which
is a substance of lipid nature. According to SEECERS and collaboratorslll6 there
are 4 kinds of antithromin in plasma:
1. Antithrombin I, is identical with fibrinogen, which inactivates throm-
bin by adsorption
16
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Table 5
Scheme for the Haemorrh;J.gic Ditheses by Dr. Szirmai, 1955, Berlin. Budapest
The Haemorrhahic Diatheses Appertaining to the Different Factors of Blood-Clotting
Caused By Hereditary Constitutional Acquired
Factor I. Fibrinogen
Factor II. Prothrombin
Liver parenchyma affections
purpura Fulminans
liver affections K-Avitami-
nonosis difcumarol effect
newborns
haemophiloid of newborns
Liver affections K-Avitami-
nosis dicumarol effect of
newborns
Liver parenchyma affections
worst form
Liver parenchyma affections
K-avitaminosis Dicumarol-
effect newborns
See factor Y-x.
Haemophilia B.
Haemophilia C. stuart C2
koller
Haemophilia D.
Menses (norm) menorrha-
gies-heparinophila D.
Inflammations inflammable
haemorrhages Heparino-
philia E. Converinopathia
Fibrinolytic crisis fibrinolysophilia
I
Fibrinogenolysinephila
Fibrinogenolysophilia
Parahaemophilia carcino-
philia (SZIRMAI)
Cases of vau Belle
Alexander Owren
Haemophilia A.
Heparinphilia B.
Afibrinogenaemy
So-Called idiopathic
Hipoprothrombinaemy
So-Called hemmkorper
hemophilin (DEUTSCH)
Heparinphila A.
Rheumatism heparinophilia
C.
Factor III. Thromboplastin
Factor IV. Calcium
Factor V. (And VI)
Factos XI? PTA Factor
(ROSENTHAL)
Factor VII.
Factor VIII. Antihaemophil
globulin
Factor IX. Christmas factor
Factor X. Kolles Stuart?
I. "Hemmkorper" of thei·
phasis of blood-clotting
antithrombin antithrombo-
kinase alfa heparin (Mc
LEAN)
II. "Hommkorper" of the 2.
Phases of blood-clotting
antithromb alfaheparin
(McLEAN)
III. Beta heparin marbet
and winierstein antithrom-
boplastin antithrombin
IV. Gamma 2 Heparin
(SZIRMAI)
V. Gamma 4 Heparin
(SZIRMAI)
VI. Factor VII. Inhibitor
VII. Fibrinolysin
VIII. Fibrinogenolysin
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Serotonin I
Histamine Refractozym
(;J Antifibri- I IHipoten-~ ~ ~.9!ysin sivum
8 P.. Heparin I I I
» ....~ II 1~__Platelet~ I
~ 81~ateletJ I Platelets_
f-< Ipactor 1. I factor 2.
Platelet I Platelet
IFactor 2. I factor 4.
A.) Congenital Haemorrhagic
Thrombasthenia Glanzmann
B.) Constitutional thrombopathy
(V. WILLEBRANO, R. JURGENS)
Essential thrombopenia
(Morbns WERLHOF)
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-
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Toxic factors
(Infection intoxication)
Neurovascular factors
Diseases of deficiency
(Hormon, vitamine)
Deficiency of vitamin C
Purpura rheumatica
ISchonlein henoch)
Purpura resp. peliosis
Rheumatica (SCHNLEIN)
Purpura abdominalis
(HENSEH)
Anaphilactoid purpura
(GLANZMANN)
Capillartopicosis
(FRANK)
Haemorrhagic
Hyperergic reactions
Purpura senilis
Constitutional capillary
asthenia (KALTSTEIN)
Scurvy, Moller-Barlow-
disease Scurvy of
sucklings
I
Ill. The Teleangiectasia I
Hereditaria haemor-
rhagica (Morbus OSLER)
I
I I Purpura fulminans anti-
I coagulantis over-dosing
2. Antithrombin II represents the plasma co-factor, which is necessary for
heparin in its inhibiting action
3. Antithrombin III inactivates thrombin, by forming metathrombin with
it.
4. Antithrombin IV interferes with the conversion of prothrombin.
The number of the antithrombins has been augumented recently. Approxi-
mately 7 antithrombins have been described, some of which are specific against
factors V, VII, VIII or IX and others which non-specifically interfere with
blood coagulation. Antithrombin VI among these antithrombins deserves special
mention.
There are inhibitors in fibrinolysis, too. TOCANTINS1:o believes that under
pathologic conditions, a specific inhihitor of plasmakinase of lipid nature, may
appear.
Clotted blood is lysed after some time has elapsed. It has been shown that
this fibrinolytic action is an enzymatic process (ASTRUplll, FERGUSON1l2, NOLFll3 ,
ASTRUpl19). It occurs by the conversion of an inactive substance (profibrinolysin,
plasminogen or prolysin) into the active form, fibrinolysin. This activation
takes place through the catalyzing influence of fibrinokinase. Fibrinolysin or
plasmin can lyse fibrinogen as well as fibrin. Its action is inhibited by anti-
fibrinolysin or antiplasmin. STEFANINI and GENDEL1l4 showed that ACTH and
cortisone are effective therapeutically in preventing fibrinolytic crisis in clinic.
This may especially be useful in premature separation of placenta (KAESERllO,
LORAND149, SZIRMAI132) and in bases of prostatic cancer (RATNOFFllO, TAGNON et
18
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Table 6 Schema of the Fibrinolysis after SZlRMAI (1961)
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alllO ).
The activation of profibrinolysine or plasminogen (into the form of fibrino-
lysine or plasmin) occurs in the following manners:
1. Spontaneous activation under unknown influences
2. In vitro activation through chlorofor~ treantment
3. Under the influence of enzymes derived from hemolytic streptococci,
Namely streptokinase, and
4. Under the influence of tissue fibrinokinase.
In all cases with increased fibrinolytic activity one may detect a pathologic
process that can explain its presence.
All the factors which we quoted in this article have many synonyms that
are shown in the tables that follow concerning the factors or the properties of
various hemorrhagic states (for example Table 6).
SUMMARY
The authors give an account of the important developments in blood coagu-
lation knowledge from the times of Malpighi and Moravitz to data. The article
is followed by original tables providing a general and comprehensive view on
blood coagulation, hemorrhagic syndromes and fibrinolysis.
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